Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Clin Toxicol (Phila) ; 54(7): 597-600, 2016 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-27219910

RESUMEN

CONTEXT: Paralepistopsis acromelalga, formerly known as Clitocybe acromelalga, is a rare poisonous mushroom. The mycotoxins in this mushroom cause symptoms resembling those of erythromelalgia; however, its pathogenesis remains unclear. In this report, a patient who received nicotinic acid treatment for P. acromelalga poisoning and radiological evaluation for erythromelalgia has been presented. Case detail: A 59-year-old woman was hospitalized for redness, swelling, and burning pain in her extremities that rendered difficulty in walking, and a diagnosis of P. acromelalga poisoning was made by detailed interview and mushroom identification. She was treated with intravenous nicotinic acid for 17 days followed by oral nicotinic acid amide for 2 months. She exhibited rapid symptomatic improvement and walked independently after 11 days of initial treatment. Initial MRI of her feet revealed toe-dominated subcutaneous thickening. After nicotinic acid treatment, those radiological findings improved dramatically. DISCUSSION: The subcutaneous thickening evident on MRI indicated P. acromelalga poisoning-induced erythromelalgia involved subcutaneous inflammatory edema. The typical duration of edema without treatment is more than a month. The improvement on MRI after nicotinic acid treatment indicated that the adequate vasodilation induced by nicotinic acid contributed to resolution of the symptoms. Nicotinic acid was associated with the improvement of the edematous changes caused by the P. acromelalga intoxication.


Asunto(s)
Agaricales , Imagen por Resonancia Magnética , Intoxicación por Setas/tratamiento farmacológico , Micotoxinas/envenenamiento , Niacina/uso terapéutico , Administración Intravenosa , Relación Dosis-Respuesta a Droga , Eritromelalgia/tratamiento farmacológico , Eritromelalgia/etiología , Femenino , Hospitalización , Humanos , Persona de Mediana Edad , Intoxicación por Setas/complicaciones , Intoxicación por Setas/diagnóstico
2.
Life Sci ; 95(1): 22-8, 2014 Jan 24.
Artículo en Inglés | MEDLINE | ID: mdl-24368140

RESUMEN

AIMS: Transplantation of bone marrow mononuclear cells (BMMCs) exerts neuroprotection against cerebral ischemia. We examined the therapeutic timepoint of allogeneic BMMC transplantation in a rat model of focal cerebral ischemia, and determined the effects of repeated transplantation outside the therapeutic window. MAIN METHODS: Male Sprague-Dawley rats were subjected to 90 minute focal cerebral ischemia, followed by intravenous administration of 1 × 10(7) allogeneic BMMCs or vehicle at 0, 3 or 6 h after reperfusion or 2 × 10(7) BMMCs 6 h after reperfusion. Other rats administered 1 × 10(7) BMMCs at 6 h after reperfusion received additional BMMC transplantation or vehicle 9 h after reperfusion. Infarct volumes, neurological deficit scores and immunohistochemistry were evaluated 24 or 72 h after reperfusion. KEY FINDINGS: Infarct volumes at 24 h were significantly decreased in transplantation rats at 0 and 3 h, but not at 6 h, after reperfusion, compared to vehicle-treatment. Even high dose BMMC transplantation at 6h after reperfusion was ineffective. Repeated BMMC transplantation at 6 and 9h after reperfusion reduced infarct volumes and significantly improved neurological deficit scores at 24 and 72 h. Immunohistochemistry showed repeated BMMC transplantation reduced ionized calcium-binding adapter molecule 1, 4-hydroxy-2-nonenal and 8-hydroxydeoxyguanosine expression at 24 and 72 h after reperfusion. SIGNIFICANCE: Intravenous allogeneic BMMCs were neuroprotective following transient focal cerebral ischemia, and the therapeutic time window of BMMC transplantation was >3 h and <6 h after reperfusion in this model. Repeated transplantation at 6 and 9 h after reperfusion suppressed inflammation and oxidative stress in ischemic brains, resulting in improved neuroprotection.


Asunto(s)
Trasplante de Médula Ósea/métodos , Lesiones Encefálicas/terapia , Ataque Isquémico Transitorio/complicaciones , Leucocitos Mononucleares/trasplante , 8-Hidroxi-2'-Desoxicoguanosina , Aldehídos/metabolismo , Animales , Lesiones Encefálicas/etiología , Proteínas de Unión al Calcio/metabolismo , Desoxiguanosina/análogos & derivados , Desoxiguanosina/metabolismo , Modelos Animales de Enfermedad , Inmunohistoquímica , Inflamación/etiología , Inflamación/terapia , Masculino , Proteínas de Microfilamentos/metabolismo , Estrés Oxidativo , Ratas , Ratas Sprague-Dawley , Factores de Tiempo , Trasplante Homólogo
4.
Intern Med ; 52(1): 115-7, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23291685

RESUMEN

We herein report the case of a 75-year-old woman with a paradoxical cerebral air embolism (CAE). She developed a bilateral visual disturbance at the time of needle puncture during a computed tomography (CT)-guided percutaneous needle lung biopsy in the face down position. The air density within the descending aorta on chest CT suggested the presence of a cerebral air embolism. Brain MRI demonstrated increased signal intensity in the bilateral occipital lobes on diffusion-weighted images. Usually, CAE occurs predominantly in the right hemisphere for anatomical reasons. The face down position and the anatomical features of the right subclavian artery, which diverges backward from the brachiocephalic artery, might explain such a unique distribution of CAE in this patient.


Asunto(s)
Biopsia con Aguja/efectos adversos , Embolia Aérea/etiología , Oxigenoterapia Hiperbárica/métodos , Enfermedad Iatrogénica , Biopsia Guiada por Imagen/efectos adversos , Neoplasias Pulmonares/patología , Anciano , Biopsia con Aguja/métodos , Embolia Aérea/diagnóstico , Embolia Aérea/terapia , Femenino , Estudios de Seguimiento , Humanos , Biopsia Guiada por Imagen/métodos , Imagen por Resonancia Magnética/métodos , Posición Prona , Enfermedades Raras , Medición de Riesgo , Tomografía Computarizada por Rayos X/métodos , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA